HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "BCMA-targeted CAR T-cell therapy"

Outcomes are poor in triple-class exposed patients with relapsed and refractory multiple myeloma ( RRMM ) who progress on immunomodulatory agents ( IMiDs ), proteasome inhibitors ( PIs ), and CD38 ant ...